The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence ...

克拉屈滨，商品名Mavenclad，用于治疗患有高度活跃的复发缓解型多发性硬化症的成年人。 克拉屈滨 10 毫克；片剂。 克拉屈滨对多发性硬化症患者发挥治疗作用的机制尚未完全阐明，但被认为与通过损害 DNA 合成对 B 和 T 淋巴细胞产生细胞毒性作用有关，从而 ...

No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

A take-at-home tablet for multiple sclerosis (MS) is set to be more broadly rolled out on the NHS, potentially benefiting ...

The Merck KGaA collaborated with actress and patient advocate Selma Blair for the I’m Ready campaign. When EMD Serono embarked on a campaign to empower patients living with relapsing multiple ...

Merck is looking for new assets as one of its key growth drivers, multiple sclerosis drug Mavenclad, will face patent expiry in 2026. The German company’s goal is to achieve a 50-50 split ...